Edgewise Therapeutics, Inc. (NASDAQ:EWTX) is among the 14 best booming stocks to buy right now. The stock is surging and has ...

BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that the company will present data on sevasemten, an ...

Edgewise Therapeutics plans to meet with regulators in the U.S. and Europe to discuss how much clinical trial evidence it needs to seek expedited approval of its experimental drug for a form of ...

Edgewise Therapeutics, Inc. (NASDAQ:EWTX) shares are trading higher Friday after the company announced the pricing of its $240 million underwritten offering of 21,818,182 shares at $11 per share.

Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today provided updates on the Company's clinical programs and highlighted major milestones for 2026.

Edgewise Therapeutics (EWTX) drew fresh attention after its J.P. Morgan Healthcare Conference update, where management detailed timelines for key 2026 milestones and potential regulatory steps across ...

- Trial to inform the disease progression of individuals with BMD - “The severity and progression of symptoms common in BMD, like progressive muscle weakness, vary from person to person and have posed ...

The biotech gifted quite a holiday present to its investors. An investigational drug continues to show significant promise. That morning, Edgewise presented interim data from its ongoing Phase 2 ...

J.P. Morgan analyst Tessa Romero has maintained their bullish stance on EWTX stock, giving a Buy rating yesterday. Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks! Easily ...

BOULDER, Colo., Nov. 10, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and ...

BOULDER, Colo., Nov. 12, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel ...

BURLINGTON, Mass.--(BUSINESS WIRE)--Edgewise Networks, the industry’s first microsegmentation platform based on software identity, today announced $11 million in new funding led by existing investors ...